All In Biotech

Drug Trial Radar · NCT04057898

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

234

Actual

Start

May 28, 2020

Primary completion

Apr 2027

Study completion Apr 2028

Sponsor

Lead sponsor
MediciNovaIndustry
Sponsor type
Industry
First posted
Aug 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • MN-166Drug

    Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.

  • placeboDrug

    Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in ALSFRS-R score at Month 12 (or last measurement before death in case of censoring) and survival time.Time frame: 12 months

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California

    Orange, California

  • Mayo Clinic

    Jacksonville, Florida

  • Augusta University

    Augusta, Georgia

  • Indiana University IU Health Neuroscience Center

    Indianapolis, Indiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Hennepin Healthcare Research Institute

    Minneapolis, Minnesota

  • SUNY Upstate Medical University

    Syracuse, New York

  • Duke University

    Durham, North Carolina

  • Lehigh Valley Health Network

    Allentown, Pennsylvania

  • University of Virginia Health System

    Charlottesville, Virginia

  • Hopital de L'Enfant-Jesus, CHU de Quebec-Universite Laval

    Québec, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • McMaster University Medical Center

    Hamilton, Ontario, Canada

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, Canada

  • University of Saskatchewan - Sastakoon Hospital

    Saskatoon, Saskatchwean, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.